May 10, 2007
Gilead Sciences Announces Senior Management Promotion
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 10, 2007--Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Paul Carter to Senior Vice President, International Commercial Operations. Mr. Carter is responsible for the company's commercial organization in all territories outside North America, reporting to Kevin Young, Gilead's Executive Vice President, Commercial Operations. With his promotion to Senior Vice President, Mr. Carter will join Gilead's Executive Committee.
Mr. Carter joined Gilead in April 2006 to lead the company's European commercial organization. In October 2006 his role was expanded to encompass all commercial markets outside of North America. Prior to joining Gilead, Mr. Carter spent 14 years in positions of increasing responsibility at GlaxoSmithKline, including the roles of a General Manager in Europe and a Regional Head of international business in Asia. Earlier in his career, he worked for Arthur Andersen's London-based practice. Mr. Carter holds a degree in Business Studies from Ealing School of Business and Management (now merged into Thames Valley University) and is a fellow of the United Kingdom's Chartered Institute of Management Accountants.
"Gilead's International Operations have grown significantly under Paul's leadership, with international sales now accounting for more than 40 percent of Gilead's product revenues," said Mr. Young. "Paul's experience and in-depth knowledge of international markets will be instrumental as our portfolio of commercial products continues to grow and as we expand our geographic reach."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.